

PC/INOS/00005



सर्वानन्द जयते




GOVERNMENT OF INDIA  
MINISTRY OF COMMERCE & INDUSTRY  
PATENT OFFICE, DELHI BRANCH  
W - 5, WEST PATEL NAGAR  
NEW DELHI - 110 008.

I, the undersigned being an officer duly authorized in accordance with the provision of the Patent Act, 1970 hereby certify that annexed hereto is the true copy of the Application, Provisional and Complete Specification filed in connection with Application for Patent No.22/Del/2004 dated 06<sup>th</sup> January 2004.

Witness my hand this 2nd day of May 2005.

(S.K. PANGASA)

Assistant Controller of Patents & Designs



Best Available Copy

0022 DE 04

FORM 1

THE PATENT ACT, 1970 JAN 004  
(39 of 1970)

APPLICATION FOR GRANT OF A PATENT

New Delhi  
Received Re 300/- in cash.  
Cheque/M.O./P.O./D.D.  
on

on 06 JAN 2004

Vide Entry No. 6297 in the

Register of Valuables

A.O. INVENTOR Cashier

BY THE ASSIGNEE AND LEGAL REPRESENTATIVE OF THE TRUE AND FIRST INVENTOR

(See Section 7, 5 (2), 54 and 135, rule 39)

We, PANACEA BIOTEC LIMITED of B-1 ,Extn. A/27 Mohan Co-operative, Indl. Estate, Mathura Road, New Delhi – 110044, A Company registered under “The Companies Act 1956.

hereby declare :-

- (1) That we are in possession of an invention for :- **A PROCESS FOR THE PREPARATION OF NOVEL CONTROLLED RELEASE ANTIBIOTIC COMPOSITIONS**.
- (ii) That the provisional specification relating to this invention is filed with this application
- (iii) That there is no lawful ground of objection to the grant of a patent to us.
- (iv) Further declare that the inventors for the said invention are

RAJESH JAIN  
Joint Managing Director  
Panacea Biotec Limited.,  
B-1 ,Extn. A/27 Mohan Co-operative,  
Indl. Estate, Mathura Road,  
New Delhi – 110044  
INDIAN.

Dr. Kour Chand Jindal  
Vice President  
Panacea Biotec Limited.,  
B-1 ,Extn. A/27 Mohan Co-operative,  
Indl. Estate, Mathura Road,  
New Delhi – 110044  
INDIAN

SUKHJIT SINGH  
G.M Research Development  
Panacea Biotec Limited.,  
B-1 ,Extn. A/27 Mohan Co-operative,  
Indl. Estate, Mathura Road,  
New Delhi – 110044  
INDIAN.

- (V) That we are assignee of the true and first inventors.
- (v) That our address for service in India is as follows :

Nagpaul & Associates  
Patent & Trade Mark Attorneys  
5/10, West Patel Nagar  
New Delhi – 110008.

(vii) Following declaration was given by the inventors:

We, the true and first inventors for this invention declare that the applicants herein are our assignee.

Rajesh Jain

RAJESH JAIN  
Joint Managing-Director  
Panacea Biotec Limited.,  
B-1 ,Extn. A/27  
Mohan Co-operative,  
Indl. Estate, Mathura Road,  
New Delhi – 110044  
INDIAN.

K. Jindal

DR. KOUR CHAND JINDAL  
Executive Vice President – R & D  
Panacea Biotec Limited.,  
B-1 ,Extn. A/27  
Mohan Co-operative,  
Indl. Estate, Mathura Road,  
New Delhi – 110044  
INDIAN.

Sukhjeet Singh

SUKHJEET SINGH  
General Manager – R & D  
Panacea Biotec Limited.,  
B-1 ,Extn. A/27  
Mohan Co-operative,  
Indl. Estate, Mathura Road,  
New Delhi – 110044  
INDIAN.

(viii) That the best of my knowledge, information and belief, the facts and matters stated herein are correct and there is no lawful ground of objection to the grant of patents.

(ix) Following are the attachments with the application.

- a) Provisional Specification (3 copies)  
b) Power of Authority.  
c) Fee Rs. 3000/- by <sup>Cash</sup> cheque bearing No.

dated

Drawn on

We request that a patent may be granted to us for the said invention.

Dated this 61<sup>st</sup> day of JANUARY, 2004

For Panacea Biotec Limited.,

Rajesh Jain

Rajesh Jain  
Joint Managing Director

TO,  
THE CONTROLLER OF PATENTS  
THE PATENT OFFICE  
NEW DELHI

FORM 2

0022 04

THE PATENTS ACT, 1970  
(39 OF 1970)  
Provisional Specification

(see Section 10; Rule 13)

16 JAN 2004

A PROCESS FOR THE PREPARATION OF CONTROLLED RELEASE  
ANTIBIOTIC COMPOSITIONS

Panacea Biotec Ltd.  
B-1 Extn. A-27, Mohan Co-operative Industrial Estate,  
Mathura Road,  
New Delhi - 110 044

The following specification describes the nature of this invention:

## **PROCESS FOR THE PREPARATION OF CONTROLLED RELEASE ANTIBIOTIC COMPOSITIONS**

### **FIELD OF THE INVENTION**

The present invention relates to process for the preparation of controlled release compositions of antibiotic, specifically Amoxycillin either alone or in combination with other antibiotic(s). The controlled release compositions are of disintegrating, mucoadhesive type.

The controlled release composition is useful in providing therapeutically effective levels of the said antibiotic for extended periods of time. Moreover the said composition is not expected to compromise the bioavailability of the antibiotic under fed or fasted conditions.

### **BACKGROUND OF THE INVENTION**

Amoxycillin is a beta-lactam widely used as a broad-spectrum antibiotic for treatment of a variety of common bacterial infections. Amoxycillin has known susceptibility to inhibition by beta-lactamases produced by resistant organisms. Amoxycillin is available in a variety of formulations, for instance as capsules, tablets, dry powders for reconstitution, chewable tablets, dispersible tablets etc. Amoxycillin is available as tablets of different strengths such as 250 mg, 500 mg, 875 mg etc. The standard adult dose is 250 mg to 500 mg three times a day (tid). In addition, the 875 mg tablet is intended for dosing twice daily (bid) instead of 500 mg tid. A high dose of 3 g, bid is recommended for treatment of recurrent purulent infection of respiratory tract. Use of 1 g Amoxycillin is recommended as one arm of combination therapy, for eradication of helicobacter pylori in peptic ulcer disease.

In the past, attempts have been made to develop modified release/controlled release formulations of Amoxycillin. Such modified/controlled release tablets may provide better patient compliance since they need to be administered twice daily as compared to the 500 mg dose given tid.

European patent number EP1044680 discloses bilayered tablets comprising of an immediate release dose of a part of Amoxycillin and potassium clavulanate and a controlled release dose of a second part of Amoxycillin. The controlled release layer is a

hydrophilic matrix. The above said composition suffers from the drawback that it requires excess quantities of excipients for preparing bilayered tablets. This combined with the high dose of Amoxycillin results in a product which is too bulky and difficult to administer.

- 5 US Patent no. 5,690,959 discloses a composition prepared using hydrophobic material manufactured by a process of thermal infusion. Amoxycillin, being temperature sensitive, may undergo degradation if subjected to high temperatures for longer periods of time.

US Patent no. 6,399,086 discloses a pharmaceutical composition of Amoxycillin  
10 wherein 50% of the drug is released within 3-4 hours. The said composition is based on hydrophilic erodible polymers.

US Patent no. 6,368,635 discloses a solid matrix composition which is solid at ambient temperature, which comprises a viscogenic agent, such as an acrylic acid polymer, capable of developing viscosity on contact with water, as dispersed at least in the  
15 neighborhood of the surface layer of a matrix particle containing a polyglycerol fatty acid ester or a lipid and an active ingredient. The matrix may be such that a matrix particle containing a polyglycerol fatty acid ester or a lipid and an active ingredient has been coated with a coating composition containing at least one viscogenic agent. Such composition can adhere to the digestive tract and remain there for a prolonged period of  
20 time, thereby increasing the bioavailability of the active ingredient. Such gastric mucosa-adherent particles have unpredictable residence time in the stomach and are highly influenced by the gastric contents. Bioavailability of active agents from such compositions are highly variable..

European patent no. EP0526862 discloses a pharmaceutical composition of Amoxycillin  
25 with prolonged residence due to high density of the composition. The said composition suffers from the drawback that non-uniform release of active ingredient results due to variable passage of tablet into intestine by virtue of density itself resulting in significant bioavailability loss.

Hilton and Deasy, [J. Pharm. Sci. 82(7):737-743 (1993)] describe a controlled-release  
30 tablet of Amoxycillin trihydrate based on the enteric polymer hydroxypropylmethyl cellulose acetate succinate. This polymer suppressed the release of the drug in the presence of gastric pH but could enhance its release in the small intestine. Therefore,

such a formulation cannot give the desired burst effect outlined in the present invention. Single dose studies with a panel of fasting subjects showed that the tablets had a relative bioavailability of only 64.4%, probably because of the poorer absorption of Amoxycillin from the distal jejunum and ileum than from the duodenum and proximal jejunum. Other pharmacokinetic parameters confirmed a lack of therapeutic advantage of these factors over an equivalent dose of conventional capsule.

Hilton and Deasy [Int. J. Pharm. 86(1):79-88 (1992)] also describe a floating tablet of Amoxycillin trihydrate. A bilayer tablet was initially formed in which the controlled-release drug layer consisted of Amoxycillin and hydroxypropyl cellulose. This layer was bonded to a gas generating layer. However, when the two layers were joined together, the composite tablet failed to float and prematurely split along the joining of the two layers. Consequently, it was decided to abandon this approach in favor of a single-layer floating tablet. This tablet remained buoyant for 6 hours and had satisfactory in vitro sustained release. However, compared with conventional capsules in fasting humans at 500 mg equivalent dose of Amoxycillin, the relative bioavailability of the tablets were 80.5% and other pharmacokinetic parameters  $T(0.1 \text{ mug/ml})$  and  $T(0.5\text{mug/ml})$  corresponding to the length of time for which the serum levels remained greater than or equal to 0.1 mug/ml and 0.5 mug/ml, respectively, indicated lack of improved efficacy.

Uchida et al. [Chem. Pharm. Bull. 37(12):3416-3419 (1989)] describe a preparation of Amoxycillin, microencapsulated in ethyl cellulose. These micro-capsules exhibited a sustained-release effect when administered to dogs. However, such effect could be foreseen, since the gastric pH of the dogs which were tested, is considerably higher than human gastric pH (pH of about 6 in beagle dogs, compared to pH of about 2 in humans). The Amoxycillin is much less soluble at pH 6 than at pH 2. One would expect to obtain a very quick release of the drug from the same microcapsules if administered to humans. Hence, such combination would not provide a controlled release of Amoxycillin.

Arancibia et al. [Int. J. Clin. Pharmacol. Ther. Toxicol. 25(2):97-100 (1987)] investigated the pharmacokinetics and bioavailability of Amoxycillin trihydrate. They refer to controlled-release tablets, the composition of which is not described. In any case, no drug was detectable after 8 hours from oral administration and therefore this formulation had no advantage over conventional formulations.

Some of the compositions discussed in the art are prepared using hydrophilic swellable polymers. However, these compositions require the use of excessive quantities of release controlling agents. This, combined with high dose of Amoxycillin, results in a product, which is too bulky to administer orally. In addition, these products have significant food effects resulting in variable bioavailability. Another approach available in the art involves the use of bioadhesive polymers. Such products are highly variable since bioadhesiveness is a property, which is significantly dependent of the gastric contents. Presence of food in the stomach reduces the bioadhesive property resulting in reduced bioavailability. A third approach discussed in the art uses enteric polymers.

5 Since Amoxycillin is predominantly absorbed from proximal part of small intestine, enteric release of the drug results in loss of bioavailability. Hence there still exists a need for developing controlled release compositions of Amoxycillin, either alone or in combination with other antibiotic(s) devoid of limitations discussed above.

10

#### **OBJECTIVE OF THE INVENTION**

15 The present invention relates to process for the preparation of controlled release composition of antibiotic, either alone or in combination with other antibiotic(s).

Preferably, the present invention describes process for the preparation of controlled release composition of Amoxycillin. More preferably, the present invention relates to

20 process for the preparation of mucoadhesive, disintegrating type controlled release composition of Amoxycillin.

#### **SUMMARY OF THE INVENTION**

The invention relates to process for the preparation of controlled release formulations of antibiotic, either alone or in combination with other antibiotic(s) for maintaining concentrations above effective levels, for extended periods of time. Preferably, the present invention relates to process for the preparation of controlled release formulation of Amoxycillin trihydrate. The release mechanism involves predominantly diffusion and the product is in the form of a rapidly disintegrating tablet.

25

30 The controlled release formulations prepared according to the present invention provides for rapidly disintegrating tablet where the granules behave as controlled release particles. These controlled release particles have mucoadhesive properties. In

addition these particles have a unique polymer combination to retard the release in the stomach while providing rapid dissolution in the alkaline contents of small intestine.

#### **DETAILED DESCRIPTION OF THE INVENTION**

- The present invention relates to process for the preparation of controlled release formulation of antibiotic, either alone or in combination with other antibiotic(s), which is a mucoadhesive, disintegrating type of product. In an embodiment, the invention describes process for the preparation of controlled release mucoadhesive, disintegrating type formulation of Amoxycillin. The said composition disintegrates into particles, which have increased residence time in the stomach.
- 5 In another embodiment, the present invention relates to process for the preparation of controlled release formulations of Amoxycillin trihydrate for maintaining concentrations above effective levels, for extended periods of time.
- 10

The controlled release formulation provides better patient compliance since they need to be administered twice daily as compared to 500 mg dose given tid.

- 15 In yet another embodiment, the controlled release formulations prepared according to the said invention disintegrates into particles, which adhere to mucosa of the stomach. These particles provide for controlled release of amoxycillin till the time they are retained in the stomach. Passage of these granules into the small intestine results in dissolution of release controlling polymers, thus liberating any residual drug entrapped
- 20
- 20 in the particles. This unique combination of polymers provides for a controlled release formulation which does not result in significant loss of bioavailability. Such a formulation does not involve the use of swellable polymers, hydrophobic waxy materials. Such a product may be prepared using polymers like polyvinyl pyrrolidone, polyvinyl acetate, methacrylic acid polymers, acrylic acid polymers; and the like either alone or in
- 25
- 25 combination thereof. The controlled release composition of the present invention may be formulated as oral dosage forms such as tablets, capsules and the like. The examples given below serve to illustrate embodiments of the present invention. However they do not intend to limit the scope of present invention.

## EXAMPLES

### Example 1

#### A. Core granules

	Ingredients	mg/tablet
5	i) Amoxycillin trihydrate (equivalent to 750 mg of Amoxycillin)	860
10	ii) Eudragit L-100	180
	iii) Polycarbophil	70
	iv) Eudragit L-100 (Binder)	20
15	v) Isopropyl Alcohol	Lost in processing
	vi) Dichloromethane	Lost in processing

#### Procedure:

1. Mix (i), (ii) and (iii).
- 15 2. Dissolve (iv) in 1:2 mixture of (v) and (vi).
3. Granulate the blend of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

#### 20 B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients	% w/w
	i) Eudragit L-100	12.5
25	ii) Polycarbophil	0.625
	iii) Triethyl citrate	2.5
	iv) Isopropyl alcohol	q.s.
	v) Dichloromethane	q.s.
	vi) Colour lake of Poncaou 4R	0.1

#### 30 Procedure :

1. Mix (i) and (ii)
2. Pass (vi) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1 : 2 mixture of (iv) and (v).
4. Add (iii) to the bulk of step 3 and stir.
- 35 5. Coat the granules of part A in FBC with the solution B.

**C. Compression**

	<b>Ingredient</b>	<b>mg/tablet</b>
i)	Amoxycillin granules (coated in B)	1399.7
ii)	Microcrystalline cellulose	100.0
5 iii)	Croscarmellose sodium	50.0
iv)	Talc	10.0
v)	Magnesium stearate	10.0

**Procedure:**

- 10 1. Mix (ii), (iii), (iv) and (v)  
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)  
3. Compress the blended granules into tablets.

**Example 2**

**A. Core granules**

	<b>Ingredients</b>	<b>mg/tablet</b>
i)	Amoxycillin trihydrate (equivalent to 750 mg of Amoxycillin)	860
ii)	Eudragit L-100	150
20 iii)	Polycarbophil	60
iv)	Eudragit L-100 (Binder)	20
v)	Isopropyl alcohol	Lost in processing
vi)	Dichloromethane	Lost in processing

**Procedure:**

1. Mix (i), (ii) and (iii).  
2. Dissolve (iv) in (v).  
3. Granulate the mass of step 1 with solution of step 2.  
4. Pass the wet mass through sieve of mesh size 20 and dry.  
30 5. Pass the dried granule through sieve of mesh size 30.

**B. Coating**

	<b>Ingredient</b>	<b>% w/w</b>
i)	Eudragit L-100	20.0
35 ii)	Polycarbophil	1.0

iii)	Triethyl citrate	-	2.0
iv)	Isopropyl alcohol	-	q.s.
v)	Dichloromethane	-	q.s.
vi)	Colour lake of Poncaou 4R	-	0.1

5

**Procedure :**

1. Mix (i) and (ii)
2. Pass (vi) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1 : 2 mixture of (iv) and (v).
- 10 4. Add (iii) to the bulk of step 3 and stir for 45 minutes.
5. Coat the granules of part A in FBC with the solution B.

**C. Compression**

	<b>Ingredient</b>		<b>mg/tablet</b>
15 i)	Amoxycillin granules (coated in B)	-	1310.0
ii)	Microcrystalline cellulose	-	150.0
iii)	Croscarmellose sodium	-	20.0
iv)	Talc	-	10.0
v)	Magnesium stearate	-	10.0

20

**Procedure:**

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

25

Dated this 6<sup>th</sup> day of January 2004

9.

05 MAY 2005

<b>FORM 1</b>  THE PATENT ACT, 1970 (39 of 1970) & The Patents Rules, 2003 APPLICATION FOR GRANT OF A PATENT (See Section 7, 54&135 and Rule 20(1))	<b>(FOR OFFICE USE ONLY)</b>  Application No. : Filing Date : Amount of Fee Paid: CBR No. : Signature :
--	---

**1. APPLICANT(S):**

Name	Nationality	Address
PANACEA BIOTEC LIMITED	An Indian Company registered under " The Companies Act 1956"	B-1 Extn.A/27Mohan Co-operative, Industrial Estate, Mathura Road, New Delhi 110044

**2. INVENTOR(S):**

Name	Nationality	Address
JAIN, Rajesh JINDAL, Kour Chand SINGH, Sukheet	ALL INDIAN CITIZENS	B-1 Extn.A/27 Mohan Co-operative, Industrial Estate, Mathura Road, New Delhi 110044

**3. TITLE OF THE INVENTION:**

"CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS"

**4. ADDRESS FOR CORRESPONDENCE OF APPLICANT/AUTHORIZED PATENT AGENT IN INDIA:**

Panacea Biotec Ltd., B-1, Extn. A/27 Mohan Co-operative, Indl. Estate, Mathura Road, New Delhi 110044  GUPTA, Bhartee IN/PA-315	Telephone No.: (0)11-51679031 / 51679076 Fax No. : (0)11-51679068 Mobile No. : E-mail : pspanwar@pblintranet.com bgupta@pblintranet.com
--	---

**5. PRIORITY PARTICULARS OF THE APPLICATION(S) FILED IN CONVENTION**

COUNTRY : NA

**6. PARTICULARS FOR FILING PATENT COOPERATION TREATY (PCT) NATIONAL**

PHASE APPLICATION : NA

**7. PARTICULARS FOR FILING DIVISIONAL APPLICATION: NA**

**8. PARTICULARS FOR FILING PATENT OF ADDITION : NA**

## 9. DECLARATIONS:

### (i) Declaration by the inventor(s)


We, the above named inventor(s) are the true and first inventor(s) for this invention declare that the applicants herein are our assignee or legal representative.

(a) Date:

(b) Signature(s) : 

(c) Name(s) : JAIN, Rajesh

JINDAL, Kour Chand





SINGH, Sukheet

### (ii) Declaration by the applicant(s) in the convention country : NA

### (iii) Declaration by the Applicant(s):

We, the applicant(s) hereby declare(s) that:

- We are in possession of the above-mentioned invention
- The provisional/complete specification relating to the invention is filed with this application.
- The invention as disclosed in the specification uses the biological material from India and the necessary permission from the competent authority shall be submitted by us before the grant of patent to us.
- There is no lawful ground of objection to the grant of the Patent to us.
- We are the assignee or legal representative of true & first inventors.
- The application or each of the applications, particulars of which are given in Para-5 was the first application in convention country/countries in respect of our invention.
- We claim the priority from the above mentioned application(s) filed in convention country/countries and state that no application for protection in respect of the invention had been made in a convention country before that date by us or by any person from which we derive the title.
- Our application in India is based on international application under Patent Cooperation Treaty (PCT) as mentioned in Para-6.
- The application is divided out of our application particulars of which are given in Para-7 and pray that this application may be treated as deemed to have been filed on \_\_\_\_\_ under sec.16 of the Act.
- The said invention is an improvement in or modification of the invention particulars of which are given in Para-8.


## 10. FOLLOWING ARE THE ATTACHMENTS WITH THE APPLICATION:

- (a) Provisional specification/complete specification
- (b) Complete specification (2 copies)
- (c) Drawings (2 copies) No. of sheets \_\_\_\_\_
- (d) Priority documents
- (e) Translation of Priority Document/Specification/International Search Report
- (f) Statement and undertaking on Form 3
- (g) Power of Authority
- (h) Declaration of inventor-ship on Form 5
- (i) Sequence listing in electronic form
- (j) .....
- (k) Fee Rs. ..... in Cash/Cheque No. .... Date ..... on ..... Bank.

We hereby declare that to the best of our knowledge, information and belief the fact and matters stated herein are correct and we request that a patent may be granted to us for the said invention.

Dated this 5 day of January, 2005

TO,  
THE CONTROLLER OF PATENTS  
THE PATENT OFFICE,  
NEW DELHI

  
Bhartee Gupta  
Manager (IP & Legal Affairs)  
Panacea Biotec Ltd.

FORM 2  
THE PATENTS ACT, 1970  
(39 of 1970)  
&  
The Patents Rules, 2003

**COMPLETE SPECIFICATION**  
(See Section 10 and Rule 13)

**CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS**

PANACEA BIOTEC LIMITED,  
an Indian Company incorporated under the Companies Act 1956  
B-1 Ext. A-27, Mohan Co-operative Industrial Estate, Mathura Road,  
New Delhi – 110 044,

The following specification particularly describes the invention and the manner in which it is to be performed.

## **Field of the invention**

The present invention relates to controlled release pharmaceutical compositions and process for preparation of such compositions, preferably comprising antibiotic(s) as active ingredient, more preferably Amoxicillin either alone or in combination with other antibiotic(s). The controlled release compositions are of disintegrating type, and additionally possess mucoadhesive properties.

The controlled release composition is useful in providing therapeutically effective levels of the said active ingredient for extended periods of time. Moreover the said composition is expected not to compromise the bioavailability of the active ingredient under fed or fasted conditions.

## **10 Background of the invention**

Amoxicillin is a beta-lactam widely used as a broad-spectrum antibiotic for treatment of a variety of common bacterial infections. Amoxicillin has known susceptibility to inhibition by beta-lactamases produced by resistant organisms. Amoxicillin is available in a variety of formulations, for instance as capsules, tablets, dry powders for reconstitution, chewable tablets, dispersible tablets etc. Amoxicillin is available as tablets of different strengths such as 250 mg, 500 mg, 875 mg etc. The standard adult dose is 250 mg to 500 mg three times a day (tid). In addition, the 875 mg tablet is intended for dosing twice daily (bid) instead of 500 mg tid. A high-dose of 3 g, bid is recommended for treatment of recurrent purulent infection of respiratory tract. Use of 1 g Amoxicillin is recommended as one arm of combination therapy, for eradication of *Helicobacter pylori* in peptic ulcer disease.

In the past, attempts have been made to develop modified release/controlled release formulations of Amoxicillin. Such modified/controlled release tablets may provide better patient compliance since they need to be administered twice daily as compared to the 500 mg dose given tid.

European patent number EP1044680 discloses bilayered tablets comprising of an immediate release dose of a part of Amoxicillin and potassium clavulanate and a controlled release dose of a second part of Amoxicillin. The controlled release layer is a hydrophilic matrix. The above said composition suffers from the drawback that it requires excess quantities of excipients for preparing bilayered tablets. This combined with the high dose of Amoxicillin results in a product which is too bulky and difficult to administer.

US Patent no. 5,690,959 discloses a composition prepared using hydrophobic material manufactured by a process of thermal infusion. Amoxicillin, being temperature sensitive, may undergo degradation if subjected to high temperatures for longer periods of time.

US Patent no. 6,399,086 discloses a pharmaceutical composition of Amoxicillin wherein 50% of  
5 the drug is released within 3-4 hours. The said composition is based on hydrophilic erodible polymers.

US Patent no. 6,368,635 discloses a solid matrix composition which is solid at ambient temperature, which comprises a viscogenic agent, such as an acrylic acid polymer, capable of developing viscosity on contact with water, as dispersed at least in the neighborhood of the  
10 surface layer of a matrix particle containing a polyglycerol fatty acid ester or a lipid and an active ingredient. The matrix may be such that a matrix particle containing a polyglycerol fatty acid ester or a lipid and an active ingredient has been coated with a coating composition containing at least one viscogenic agent. Such composition can adhere to the digestive tract and remain there for a prolonged period of time, thereby increasing the bioavailability of the active  
15 ingredient. Such gastric mucosa-adherent particles have unpredictable residence time in the stomach and are highly influenced by the gastric contents. Bioavailability of active agents from such compositions are highly variable.

European patent no. EP0526862 discloses a pharmaceutical composition of Amoxicillin with prolonged residence due to high density of the composition. The said composition suffers from  
20 the drawback that non-uniform release of active ingredient results due to variable passage of tablet into intestine by virtue of density itself resulting in significant bioavailability loss.

Hilton and Deasy, [J. Pharm. Sci. 82(7):737-743 (1993)] describe a controlled-release tablet of Amoxicillin trihydrate based on the enteric polymer hydroxypropylmethyl cellulose acetate succinate. This polymer suppressed the release of the drug in the presence of gastric pH but  
25 could enhance its release in the small intestine. Therefore, such a formulation cannot give the desired burst effect outlined in the present invention. Single dose studies with a panel of fasting subjects showed that the tablets had a relative bioavailability of only 64.4%, probably because of the poorer absorption of Amoxicillin from the distal jejunum and ileum than from the duodenum and proximal jejunum. Other pharmacokinetic parameters confirmed a lack of therapeutic  
30 advantage of these factors over an equivalent dose of conventional capsule.

Hilton and Deasy [Int. J. Pharm. 86(1):79-88 (1992)] also describe a floating tablet of Amoxicillin trihydrate. A bilayer tablet was initially formed in which the controlled-release drug

layer consisted of Amoxicillin and hydroxypropyl cellulose. This layer was bonded to a gas generating layer. However, when the two layers were joined together, the composite tablet failed to float and prematurely split along the joining of the two layers. Consequently, it was decided to abandon this approach in favor of a single-layer floating tablet. This tablet remained buoyant for 5 6 hours and had satisfactory in vitro sustained release. However, compared with conventional capsules in fasting humans at 500 mg equivalent dose of Amoxicillin, the relative bioavailability of the tablets were 80.5% and other pharmacokinetic parameters  $T(0.1 \text{ mug/ml})$  and  $T(0.5\text{mug/ml})$  corresponding to the length of time for which the serum levels remained greater than or equal to 0.1 mug/ml and 0.5 mug/ml, respectively, indicated lack of improved efficacy.

- 10 Uchida et al. [Chem. Pharm. Bull. 37(12):3416-3419 (1989)] describe a preparation of Amoxicillin, microencapsulated in ethyl cellulose. These micro-capsules exhibited a sustained-release effect when administered to dogs. However, such effect could be foreseen, since the gastric pH of the dogs which were tested, is considerably higher than human gastric pH (pH of about 6 in beagle dogs, compared to pH of about 2 in humans). The Amoxicillin is much less 15 soluble at pH 6 than at pH 2. One would expect to obtain a very quick release of the drug from the same microcapsules if administered to humans. Hence, such combination would not provide a controlled release of Amoxicillin

- 20 Arancibia et al. [Int. J. Clin. Pharmacol. Ther. Toxicol. 25(2):97-100 (1987)] investigated the pharmacokinetics and bioavailability of Amoxicillin trihydrate. They refer to controlled-release tablets, the composition of which is not described. In any case, no drug was detectable after 8 hours from oral administration and therefore this formulation had no advantage over conventional formulations.

- 25 Some of the compositions discussed in the art are prepared using hydrophilic swellable polymers. However, these compositions require the use of excessive quantities of release controlling agents. This combined with high dose of amoxicillin, results in a product, which is too bulky to administer orally. In addition, these products have significant food effects resulting in variable bioavailability. Another approach available in the art involves the use of bioadhesive polymers. Such products are highly variable since bioadhesiveness is a property, which is significantly dependent of the gastric contents. Presence of food in the stomach reduces the 30 bioadhesive property resulting in reduced bioavailability. A third approach discussed in the art uses enteric polymers. Since Amoxicillin is predominantly absorbed from proximal part of small intestine, enteric release of the drug results in loss of bioavailability. Hence there still exists a

need for developing controlled release compositions of amoxicillin, either alone or in combination with other antibiotic(s) devoid of limitations discussed above.

### **Summary of the invention**

It is an objective of the present invention to provide rapidly disintegrating oral controlled release  
5 pharmaceutical composition comprising at least one active ingredient, and a polymer system comprising of at least two polymers wherein one is an acid insoluble polymer and the other is a bioadhesive polymer, which retard the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in the pH above 5.5, optionally with other pharmaceutically acceptable excipients.

10 It is an objective of the present invention to provide rapidly disintegrating oral controlled release pharmaceutical composition comprising at least one active ingredient preferably antibiotic, more preferably amoxicillin or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.

15 It is a further objective of the present invention to provide controlled release composition comprising an antibiotic as an active ingredient in combination with at least one other antibiotic.

20 It is yet another objective of the present invention to provide process for the preparation of such composition which comprises of the following steps:

- i) mixing of active ingredient(s) and polymer(s),
- ii) optionally adding one or more other pharmaceutically acceptable excipients, and
- iii) formulation of the mixture into a suitable dosage form.

### **Detailed description of the invention**

25 The present invention relates to rapidly disintegrating oral controlled release pharmaceutical composition comprising at least one active ingredient or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof; and a polymer system, optionally with other pharmaceutically acceptable excipients. The polymer system comprises of at least two polymers, wherein one is an acid insoluble polymer and the other is a bioadhesive polymer. The  
30 polymer system retards the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in the pH above 5.5.

In an embodiment, the present invention describes controlled release mucoadhesive, disintegrating type formulation of Amoxicillin, preferably in its trihydrate form. The said composition disintegrates into particles, which have increased residence time in the stomach thus maintaining concentrations above effective levels for extended periods of time. The controlled

- 5 release formulation provides better patient compliance since they need to be administered twice daily as compared to 500 mg dose given tid.

The present invention also relates to controlled release compositions of preferably an antibiotic, more preferably amoxicillin trihydrate, either alone or in combination with other antibiotic(s) for maintaining concentrations above effective levels, for extended periods of time. The release

- 10 mechanism involves predominantly diffusion and the product is preferably in the form of a rapidly disintegrating tablet.

The controlled release compositions prepared according to the present invention provides for rapidly disintegrating tablet where the granules behave as controlled release particles. These particles have a unique polymer combination to retard the release in the stomach while providing  
15 rapid dissolution in the alkaline contents of small intestine. In addition, the controlled release compositions have bioadhesive properties.

In an embodiment of the present invention, the controlled release composition comprises an antibiotic as an active ingredient in combination with at least one other antibiotic. The antibiotics are selected from but not limited to the group comprising amoxicillin, ampicillin, cloxacillin,  
20 clavulanic acid, cephalosporins, and the like.

In an embodiment, the active ingredient of the present pharmaceutical composition is cephalexin, or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.

- 25 The polymer system of the present invention comprises of polymer system comprises of polymers selected from a group comprising polyvinyl pyrrolidone, polyvinyl acetate, methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, cellulose derivative, polyethylene oxide, chitosans, and  
30 polycarbophil, or mixtures thereof. Preferably the polymer system comprises methacrylic acid polymer and polycarbophil.

The acid insoluble polymer of the present invention is selected form but not limited to a group comprising methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, alginates, and the like; or mixtures thereof and the other is a bioadhesive polymer is selected form but not limited to a group comprising polycarbophil such as Noveon® AA1 (B. F. Goodrich Specialty Polymers), and chitosans, or mixtures thereof. Polycarbophil is a polyacrylic acid that is cross-linked with divinyl glycol.

5 The methacrylic acid polymer is selected from a group comprising but not limited to Eudragit® (Degussa) such as Eudragit® L-100, Ammonio Methacrylate Copolymer type A USP (Eudragit® RL), Ammonio Methacrylate Copolymer type B USP (Eudragit® RS), Eudragit® RSPO, Eudragit® RLPO, and Eudragit® RS30D.

10 In a preferred embodiment of the present invention, the rapidly disintegrating oral controlled release pharmaceutical composition comprises amoxicillin trihydrate; and a polymer system comprising methacrylic acid polymer and polycarbophil, optionally with other pharmaceutically acceptable excipients.

15 In an embodiment of the present invention, the ratio of methacrylic acid polymer and polycarbophil is 20:1 to 1:20 by weight of the composition. Preferably the ratio of methacrylic acid polymer and polycarbophil is 10:1 to 1:10 by weight of the composition.

20 In another preferred embodiment of the present invention, the composition additionally comprises a cellulose derivative, selected from but not limited to a group comprising alkyl cellulose such as ethyl cellulose, methyl cellulose, and the like; carboxyalkyl cellulose such as carboxyethyl cellulose, carboxymethyl cellulose, carboxypropyl cellulose, and the like, and carboxyalkyl cellulose such as hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, and the like, and hydroxypropyl alkyl cellulose such as hydroxypropyl methyl cellulose, and the like. Preferably, the cellulose derivative is alkyl cellulose such as ethylcellulose or propylcellulose.

25 The pharmaceutically acceptable excipients of the present invention are selected from the group comprising diluents disintegrants, binders, fillers, bulking agent, coating agents, plasticizers, organic solvents, colourants, stabilizers, preservatives, lubricants, glidants, chelating agents, and the like known to the art.

In an embodiment of the present invention is provided a process for preparation of composition as herein described which comprises of the following steps:

- i) mixing of active ingredient(s) and polymer(s),
- ii) optionally adding one or more other pharmaceutically acceptable excipients; and
- 5 iii) formulation of the mixture into a suitable dosage form.

In an embodiment, the composition of the present invention is in the form of tablets. The tablets can be prepared by either direct compression, dry compression (slugging), or by granulation.

10 The granulation technique is either aqueous or non-aqueous. Preferably, the tablets of the present invention are prepared by non-aqueous granulation technique. The non-aqueous solvent used is selected from a group comprising ethanol or isopropyl alcohol.

In yet another embodiment, the controlled release formulations prepared according to the present invention disintegrates into particles, which adhere to mucosa of the stomach. These particles provide for controlled release of Amoxicillin till the time they are retained in the stomach. Passage of these granules into the small intestine results in dissolution of release controlling 15 polymers, thus liberating any residual drug entrapped in the particles. This unique combination of polymers provides for a controlled release formulation which does not result in significant loss of bioavailability. Such a formulation does not involve the use of swellable polymers, hydrophobic waxy materials. Such a product may be prepared using polymers like polyvinyl pyrrolidone, polyvinyl acetate, methacrylic acid polymers, acrylic acid polymers; and the like 20 either alone or in combination thereof.

The controlled release composition of the present invention may be formulated as oral dosage forms such as tablets, capsules and the like.

25 The examples given below serve to illustrate embodiments of the present invention. However they do not intend to limit the scope of present invention.

## EXAMPLES

### Example 1

#### A. Core granules

30	Ingredients	mg/tablet
i)	Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	860
ii)	Eudragit® L-100	180

iii)	Polycarbophil	-	70
iv)	Eudragit® L-100 (Binder)	-	20
v)	Isopropyl Alcohol	-	Lost in processing
vi)	Dichloromethane	-	Lost in processing

5

**Procedure:**

1. Mix (i), (ii) and (iii).
2. Dissolve (iv) in 1:2 mixture of (v) and (vi).
3. Granulate the blend of step 1 with solution of step 2.
- 10 4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

**B. Coating of the granules in FBC (Fluid Bed Coater)**

	<b>Ingredients</b>	<b>% w/w</b>
15 i)	Eudragit® L-100	- 12.5
ii)	Polycarbophil	- 0.625
iii)	Triethyl citrate	- 2.5
iv)	Isopropyl alcohol	- q.s.
v)	Dichloromethane	- q.s.
20 vi)	Colour lake of Poncaou 4R	- 0.1

**Procedure :**

1. Mix (i) and (ii)
2. Pass (vi) through sieve of mesh no. 120.
- 25 3. Disperse the bulk of step 1 and 2 in 1 : 2 mixture of (iv) and (v).
4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with the solution B.

**C. Compression**

	<b>Ingredient</b>	<b>mg/tablet</b>
30 i)	Amoxicillin granules (coated in B)	- 1399.7
ii)	Microcrystalline cellulose	- 100.0
iii)	Croscarmellose sodium	- 50.0
iv)	Talc	- 10.0
35 v)	Magnesium stearate	- 10.0

**Procedure:**

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

5

**Example 2**

**A. Core granules**

	<b>Ingredients</b>	<b>mg/tablet</b>	
i)	Amoxicillin trihydrate	860	
10	(equivalent to 750 mg of Amoxicillin)		
ii)	Eudragit® L-100	150	
iii)	Polycarbophil	60	
iv)	Eudragit® L-100 (Binder)	20	
v)	Isopropyl alcohol	Lost in processing	
15	vi)	Dichloromethane	Lost in processing

**Procedure:**

1. Mix (i), (ii) and (iii).
2. Dissolve (iv) in (v).
- 20 3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

**B. Coating**

	<b>Ingredient</b>	<b>% w/w</b>	
i)	Eudragit® L-100	20.0	
ii)	Polycarbophil	1.0	
iii)	Triethyl citrate	2.0	
iv)	Isopropyl alcohol	q.s.	
30	v)	Dichloromethane	q.s.
vi)	Colour lake of Poncaou 4R	0.1	

**Procedure :**

1. Mix (i) and (ii)
- 35 2. Pass (vi) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1 : 2 mixture of (iv) and (v).

4. Add (iii) to the bulk of step 3 and stir for 45 minutes.
5. Coat the granules of part A in FBC with the solution B.

**C. Compression**

	Ingredient	mg/tablet
5	i) Amoxicillin granules (coated in B)	1310.0
	ii) Microcrystalline cellulose	150.0
	iii) Croscarmellose sodium	20.0
	iv) Talc	10.0
10	v) Magnesium stearate	10.0

**Procedure:**

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
- 15 3. Compress the blended granules into tablets.

**Example 3**

**A. Core granules**

	Ingredients	mg/tablet
20	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	860.00
	ii) Eudragit® L-100	180.00
	iii) Polycarbophil	70.00
	iv) PVP K-30	20.00
25	v) Purified Water	Lost in processing

**Procedure:**

6. Mix (i), (ii) and (iii) pass through mesh size 30.
7. Dissolve (iv) in water
- 30 8. Granulate the mass of step 1 with solution of step 2.
9. Pass the wet mass through sieve of mesh size 20 and dry.
10. Pass the dried granule through sieve of mesh size 30.

**B. Coating of the granules in FBC (Fluid Bed Coater)**

	Ingredients	% w/w
35	i) Eudragit® NE 30 D (Dry polymer weight of 30% w/w dispersion)	12.50

ii)	Polycarbophil	0.625
iii)	Talc	6.25
iv)	Colour Lake of Ponceau 4R	0.10
v)	Purified Water	Lost in processing

5

**Procedure:**

6. Mix (ii), (iii) and (iv)
7. Pass mass of step 1 through sieve of mesh no. 100.
8. Disperse the bulk of step 2 in (v) and pass through a Colloid mill.
- 10 9. Add (i) to the bulk of step 3 and stir.
10. Coat the granules of part A in FBC with solution of step 4.

**C. Compression**

	<b>Ingredients</b>	<b>mg/tablet</b>
15 i)	Amoxicillin granules (coated in B)	- 1350.09
ii)	Microcrystalline cellulose	- 100.00
iii)	Croscarmellose sodium	- 50.00
iv)	Talc	- 10.00
v)	Magnesium stearate	- 10.00

20

**Procedure:**

4. Mix (ii), (iii), (iv) and (v)
5. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
6. Compress the blended granules into tablets.

25

**Example 4****A. Core granules**

	<b>Ingredients</b>	<b>mg/tablet</b>
i)	Amoxicillin trihydrate	- 860.00
30	(equivalent to 750 mg of Amoxicillin)	
ii)	Eudragit® L-100	- 100.00
iii)	Polycarbophil	- 40.00
iv)	Eudragit® L-30-D55	- 150.00
	(Dry polymer weight of 30% w/w dispersion)	
35 v)	Purified Water	- Lost in processing

**Procedure:**

1. Mix (i), (ii) and (iii) and pass through mesh size 30.
2. Disperse (iv) in water
3. Granulate the mass of step 1 with dispersion of step 2.
- 5 4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

**B. Coating of the granules in FBC (Fluid Bed Coater)**

	<b>Ingredients</b>	<b>% w/w</b>
10	i) Eudragit® L-30-D55 (Dry polymer weight of 30% w/w dispersion)	12.50
	ii) Polycarbophil	0.625
	iii) Talc	6.25
	iv) Triethyl Citrate	1.25
15	v) Colour Lake of Ponceau 4R	0.10
	vi) Purified Water	Lost in processing

**Procedure :**

1. Mix (ii), (iii) and (v).
- 20 2. Pass mass of step 1 through sieve of mesh no. 100.
3. Disperse the bulk of step 2 in (vi) and pass through a Colloid mill.
4. Add (i) and (iv) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

**25 C. Compression**

	<b>Ingredients</b>	<b>mg/tablet</b>
	i) Amoxicillin granules (coated in B)	1388.34
	ii) Microcrystalline cellulose	100.00
	iii) Croscarmellose sodium	50.00
30	iv) Talc	10.00
	v) Magnesium stearate	10.00

**Procedure:**

1. Mix (ii), (iii), (iv) and (v)
- 35 2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

**Example 5****A. Core granules**

	<b>Ingredients</b>	<b>mg/tablet</b>
5	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	860.00
	ii) Eudragit® L-100	120.00
	iii) Polycarbophil	40.00
10	iv) Eudragit® L-30-D55 (Dry polymer weight of 30% w/w dispersion)	80.00
	v) Purified Water	Lost in processing

**Procedure:**

1. Mix (i), (ii) and (iii) pass through mesh size 30.
- 15 2. Disperse (iv) in water
3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

**20 B. Coating of the granules in FBC (Fluid Bed Coater)**

	<b>Ingredients</b>	<b>% w/w</b>
	i) Eudragit® L-30-D55 (Dry polymer weight of 30% w/w dispersion)	16.00
25	ii) Polycarbophil	0.09
	iii) Talc	8.00
	iv) Triethyl Citrate	3.20
	v) Colour Lake of Ponceau 4R	0.10
	vi) Purified Water	Lost in processing

**30 Procedure :**

1. Mix (ii), (iii) and (v).
2. Pass bulk of step 1 through sieve of mesh no. 100.
3. Disperse the bulk of step 2 in (vi) and pass through a Colloid mill.
4. Add (i) and (iv) to the bulk of step 3 and stir.
- 35 5. Coat the granules of part A in FBC with solution of step 4.

**C. Compression**

	<b>Ingredients</b>	<b>mg/tablet</b>
i)	Amoxicillin granules (coated in B)	1401.29
ii)	Microcrystalline cellulose	100.00
5 iii)	Croscarmellose sodium	50.00
iv)	Talc	10.00
v)	Magnesium stearate	10.00

**Procedure:**

- 10 1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

**Example 6**

**A. Core granules**

	<b>Ingredients</b>	<b>mg/tablet</b>
i)	Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	860.00
ii)	Ethyl Cellulose M 20	100.00
20 iii)	Polycarbophil	40.00
iv)	Eudragit® L-30-D55 (Dry polymer weight of 30% w/w dispersion)	20.00
v)	Purified Water	Lost in processing

**Procedure:**

1. Mix (i) and (iii) pass through mesh size 30.
2. Pass (ii) through sieve of mesh size 100 and blend with mass of step 1.
3. Disperse (iv) in Purified Water.
4. Granulate the mass of step 2 with solution of step 3.
- 30 5. Pass the wet mass through sieve of mesh size 20 and dry.
6. Pass the dried granule through sieve of mesh size 30.

**B. Coating of the granules in FBC (Fluid Bed Coater)**

	<b>Ingredients</b>	<b>% w/w</b>
35 i)	Eudragit® L-30-D55 (Dry polymer weight of 30% w/w dispersion)	12.50

ii)	Talc	6.25
iii)	Triethyl Citrate	3.75
iv)	Colour Lake of Ponceau 4R	0.10
v)	Purified Water	Lost in processing

5

**Procedure :**

1. Mix (iii) and (v).
2. Pass mass of step 1 through sieve of mesh no. 100.
3. Disperse the bulk of step 2 in (v) and pass through a Colloid mill.
- 10 4. Add (i) and (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

**C. Compression**

	<b>Ingredients</b>	<b>mg/tablet</b>
15 i)	Amoxicillin granules (coated in B)	1251.34
ii)	Microcrystalline cellulose	100.00
iii)	Croscarmellose sodium	50.00
iv)	Talc	10.00
v)	Magnesium stearate	10.00

20

**Procedure:**

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

25

**Example 7****A. Core granules**

	<b>Ingredients</b>	<b>mg/tablet</b>
i)	Amoxicillin trihydrate	860.00
30	(equivalent to 750 mg of Amoxicillin)	
ii)	Ethyl Cellulose	20.00
iii)	Polycarbophil	40.00
iv)	Eudragit® L100	50.00
v)	Eudragit® L-30-D55	100.00
35	(Dry polymer weight of 30% w/w dispersion)	
vi)	Purified Water	Lost in processing

**Procedure:**

1. Mix (i), (iii) and (iv) pass through mesh size 30.
2. Pass (ii) through sieve of mesh size 100 and blend with mass of step 1.
- 5      3. Disperse (v) in Purified Water.
4. Granulate the mass of step 2 with solution of step 3.
5. Pass the wet mass through sieve of mesh size 20 and dry.
6. Pass the dried granule through sieve of mesh size 30.

**10    B. Coating of the granules in FBC (Fluid Bed Coater)**

	<b>Ingredients</b>	<b>% w/w</b>
i)	Eudragit® L-30-D55 (Dry polymer weight of 30% w/w dispersion)	12.50
ii)	Polycarbophil	0.625
15    iii)	Talc	6.25
iv)	Triethyl Citrate	2.50
v)	Colour Lake of Ponceau 4R	0.10
vi)	Purified Water	Lost in processing

**20    Procedure :**

1. Mix (ii), (iii) and (v).
2. Pass mass of step 1 through sieve of mesh no. 100.
3. Disperse the bulk of step 2 in (vi) and pass through a Colloid mill.
4. Add (i) and (iv) to the bulk of step 3 and stir.
- 25    5. Coat the granules of part A in FBC with solution of step 4.

**C. Compression**

	<b>Ingredients</b>	<b>mg/tablet</b>
i)	Amoxicillin granules (coated in B)	1305.13
30    ii)	Microcrystalline cellulose	100.00
iii)	Croscarmellose sodium	50.00
iv)	Talc	10.00
v)	Magnesium stearate	10.00

**Procedure:**

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

5

**Example 8**

**A. Core granules**

	<b>Ingredients</b>	<b>mg/tablet</b>
i)	Amoxicillin trihydrate	- 860.00
10	(equivalent to 750 mg of Amoxicillin)	
ii)	Eudragit® RSPO	- 100.00
iii)	Polycarbophil	- 40.00
iv)	Eudragit® L-30-D55 (Dry polymer weight of 30% w/w dispersion)	- 100.00
15	v) Purified Water	- Lost in processing

**Procedure:**

1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Disperse (iv) in Purified Water.
- 20 3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

**B. Coating of the granules in FBC (Fluid Bed Coater)**

	<b>Ingredients</b>	<b>% w/w</b>
i)	Eudragit® L-100	- 12.50
ii)	Polycarbophil	- 0.625
iii)	Triethyl Citrate	- 2.50
iv)	Isopropyl Alcohol	- Lost in processing
30 v)	Dichloromethane	- Lost in processing
vi)	Colour Lake of Ponceau 4R	- 0.10

**Procedure :**

1. Mix (i) and (ii) and pass through mesh no. 100.
- 35 2. Pass (vi) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)

4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

**C. Compression**

	Ingredients	mg/tablet
5	i) Amoxicillin granules (coated in B)	1272.97
	ii) Microcrystalline cellulose	100.00
	iii) Croscarmellose sodium	50.00
	iv) Talc	10.00
10	v) Magnesium stearate	10.00

**Procedure:**

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
- 15 3. Compress the blended granules into tablets.

**Example 9**

**A. Core granules**

	Ingredients	mg/tablet
20	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	860.00
	ii) Eudragit RLPO	100.00
	iii) Polycarbophil	40.00
	iv) Eudragit L-30-D55 (Dry polymer weight of 30% w/w dispersion)	100.00
25	v) Purified Water	Lost in processing

**Procedure:**

1. Mix (i), (ii) and (iii) pass through mesh size 30.
- 30 2. Disperse (iv) in Purified Water
3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

**B. Coating of the granules in FBC (Fluid Bed Coater)**

	Ingredients	% w/w
35	i) Eudragit L-100	12.50

	ii)	Polycarbophil	0.625
	iii)	Triethyl Citrate	2.50
	iv)	Isopropyl Alcohol	Lost in processing
	v)	Dichloromethane	Lost in processing
5	vi)	Colour Lake of Ponceau 4R	0.10

Procedure :

1. Mix (i) and (ii) and pass through mesh no. 100.
2. Pass (vi) through sieve of mesh no. 120.
- 10 3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)
4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

	15	Ingredient	mg/tablet
i)	Amoxicillin granules (coated in B)	-	1272.97
ii)	Microcrystalline cellulose	-	100.00
iii)	Croscarmellose sodium	-	50.00
iv)	Talc	-	10.00
20 v)	Magnesium stearate	-	10.00

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
- 25 3. Compress the blended granules into tablets.

**Example 10**

A. Core granules

	30	Ingredients	mg/tablet
i)	Amoxicillin trihydrate	-	860.00
	(equivalent to 750 mg of Amoxicillin)		
ii)	Eudragit RLPO	-	100.00
iii)	Polycarbophil	-	40.00
iv)	Triethyl Citrate	-	20.00
35 v)	Eudragit L-30-D55	-	100.00
	(Dry polymer weight of 30% w/w dispersion)		

vi) Purified Water - Lost in processing

Procedure:

1. Mix (i), (ii) and (iii) pass through mesh size 30.
- 5 2. Disperse (iv) and (v) in water
3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

10 B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients	% w/w
i)	Eudragit L-100	- 12.50
ii)	Polycarbophil	- 0.625
iii)	Triethyl Citrate	- 2.50
15 iv)	Isopropyl Alcohol	- Lost in processing
v)	Dichloromethane	- Lost in processing
vi)	Colour Lake of Ponceau 4R	- 0.10

Procedure :

- 20 1. Mix (i) and (ii) pass through mesh no. 100.
2. Pass (vi) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)
4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

25

C. Compression

	Ingredients	mg/tablet
i)	Amoxicillin granules (coated in B)	- 1296.12
ii)	Microcrystalline cellulose	- 100.00
30 iii)	Croscarmellose sodium	- 50.00
iv)	Talc	- 10.00
v)	Magnesium stearate	- 10.00

Procedure:

- 35 1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)

3. Compress the blended granules into tablets.

**Example 11**

**A. Core granules**

	Ingredients	mg/tablet
5	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	860.00
10	ii) Eudragit RLPO	100.00
10	iii) Polycarbophil	40.00
iv) Triethyl Citrate		20.00
15	iv) Eudragit L-30-D55 (Dry polymer weight of 30% w/w dispersion)	100.00
v) Purified Water		Lost in processing

**15 Procedure:**

1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Disperse (iv) and (v) in Purified Water.
3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
- 20 5. Pass the dried granule through sieve of mesh size 30.

**B. Coating of the granules in FBC (Fluid Bed Coater)**

	Ingredients	% w/w
25	i) Ethyl cellulose (Surelease®) (Dry polymer weight of 25% w/w dispersion)	12.50
ii) Polycarbophil		0.18
iii) Talc		6.25
iv) Triethyl Citrate		2.50
v) Colour Lake of Ponceau 4R		0.10
30 vi) Water		Lost in processing

**Procedure :**

1. Mix (ii), (iii) and (v).
2. Pass mass of step 1 through sieve of mesh no. 100.
- 35 3. Disperse the bulk of step 2 in (vi) and pass through a Colloid mill.
4. Add (i) and (iv) to the bulk of step 3 and stir.

5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

	Ingredient	mg/tablet
5	i) Amoxicillin granules (coated in B)	- 1361.14
	ii) Microcrystalline cellulose	- 100.00
	iii) Croscarmellose sodium	- 50.00
	iv) Talc	- 10.00
	v) Magnesium stearate	- 10.00

10

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

15

Example 12

A. Core granules

	Ingredients	mg/tablet
i)	Amoxicillin trihydrate	- 860.00
20	(equivalent to 750 mg of Amoxicillin)	
ii)	Eudragit L-100	- 100.00
iii)	Polycarbophil	- 40.00
iv)	Eudragit L100	- 20.00
v)	Ethanol	- Lost in processing
25	vi) Purified Water	- Lost in processing

Procedure:

1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Dissolve (iv) in a mixture of (v) and (vi) (6:4 ratio)
- 30 3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients	% w/w
35	i) Eudragit L-100	- 12.50

ii)	Polycarbophil	-	0.625
iii)	Triethyl Citrate	-	2.50
iv)	Isopropyl Alcohol	-	Lost in processing
v)	Dichloromethane	-	Lost in processing
5 vi)	Colour Lake of Ponceau 4R	-	0.10

Procedure :

1. Mix (i) and (ii) and pass through mesh no. 100..
2. Pass (vi) through sieve of mesh no. 120.
- 10 3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)
4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

	Ingredient	mg/tablet
15 i)	Amoxicillin granules (coated in B)	1180.39
ii)	Microcrystalline cellulose	100.00
iii)	Croscarmellose sodium	50.00
iv)	Talc	10.00
20 v)	Magnesium stearate	10.00

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
- 25 3. Compress the blended granules into tablets.

**Example 13**

A. Core granules

	Ingredients	mg/tablet
30 i)	Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	860.00
ii)	Eudragit L-100	100.00
iii)	Polycarbophil	40.00
iv)	Eudragit L100	20.00
35 v)	Ethanol	Lost in processing
vi)	Purified Water	Lost in processing

**Procedure:**

1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Dissolve (iv) in a mixture of (v) and (vi) (6:4 ratio)
- 5 3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

**B. Coating of the granules in FBC (Fluid Bed Coater)**

	<b>Ingredients</b>	<b>% w/w</b>
10	i) Eudragit L-100	- 12.50
	ii) Clavulanate Potassium	- 12.25
	iii) Polycarbophil	- 0.625
	iv) Triethyl Citrate	- 2.50
15	v) Isopropyl Alcohol	- Lost in processing
	vi) Dichloromethane	- Lost in processing
	vii) Colour Lake of Ponceau 4R	- 0.10

**Procedure :**

- 20 1. Mix (i), (ii) and (iii).
2. Pass (vii) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (v) and (vi)
4. Add (iv) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

**C. Compression**

	<b>Ingredient</b>	<b>mg/tablet</b>
25	i) Amoxicillin granules (coated in B)	- 1305.34
	ii) Microcrystalline cellulose	- 100.00
30	iii) Croscarmellose sodium	- 50.00
	iv) Talc	- 10.00
	v) Magnesium stearate	- 10.00

**Procedure:**

- 35 1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

### **Example 14**

#### **A. Core granules**

	<b>Ingredients</b>	<b>mg/tablet</b>
5	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	860.00
	ii) Eudragit L-100	100.00
	iii) Polycarbophil	40.00
	iv) Eudragit L100	20.00
10	v) Ethanol	- Lost in processing
	vi) Purified Water	- Lost in processing

**Procedure:**

1. Mix (i), (ii) and (iii) pass through mesh size 30.
- 15 2. Dissolve (iv) in a mixture of (v) and (vi) (6:4 ratio)
3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

**20 B. Coating of the granules in FBC (Fluid Bed Coater)**

	<b>Ingredients</b>	<b>% w/w</b>
	i) Eudragit L-100	12.50
	ii) Polycarbophil	0.625
	iii) Triethyl Citrate	2.50
25	iv) Isopropyl Alcohol	- Lost in processing
	v) Dichloromethane	- Lost in processing
	vi) Colour Lake of Ponceau 4R	0.10

**Procedure :**

- 30 1. Mix (i) and (ii) and pass through mesh no. 100.
2. Pass (vi) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)
4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

**C. Preparation of Amoxicillin SR granules**

	<b>Ingredient</b>	<b>mg/tablet</b>
i)	Amoxicillin granules (coated in B)	1180.39
ii)	Microcrystalline cellulose	100.00
5 iii)	Croscarmellose sodium	50.00
iv)	Talc	10.00
v)	Magnesium stearate	10.00

**Procedure:**

- 10 1. Mix (ii), (iii), (iv) and (v)  
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)

**D. Preparation of Claculanate Potassium granules**

	<b>Ingredient</b>	<b>mg/tablet</b>
15 i)	Clavulanate Potassium/	250.00
	Microcrystalline Cellulose 1:1 mixture (equivalent to 125 mg Clavulanic acid)	
ii)	Croscarmellose sodium	50.00
iii)	Talc	10.00
20 iv)	Magnesium stearate	10.00

**Procedure:**

1. Mix (i), (ii), (iii) and (iv)  
2. Slug and de-slug the blend of step 1 and pass through sieve of mesh size 30.

25 **E. Compression into Inlay tablets**

Compress the granules of Amoxicillin SR granules and Clavulanate potassium granules into inlay tablets where the Clavulanate potassium granules are inlaid into the tablet of amoxicillin granules.

We Claim:

1. A rapidly disintegrating oral controlled release pharmaceutical composition comprising at least one active ingredient; and a polymer system comprising of at least two polymers, wherein one is an acid insoluble polymer and the other is a bioadhesive polymer, which retard the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in the pH above 5.5, optionally with other pharmaceutically acceptable excipients.
2. A composition according to claim 1, wherein said active ingredient is selected from a group comprising antibiotics, such as cephalosporins and penicillins, and their pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.
3. A composition according to claim 1, wherein said active ingredient is amoxicillin trihydrate.
4. A composition according to claim 1, wherein said active ingredient is cephalexin, or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.
5. A composition according to claim 1, which comprises at least two active ingredients selected from the group comprising amoxicillin, ampicillin, cloxacillin, clavulanic acid, cephalosporins, or pharmaceutically acceptable salts or derivatives thereof.
6. A composition according to claim 1, wherein the polymer system comprises of polymers selected from a group comprising polyvinyl pyrrolidone, polyvinyl acetate, methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, cellulose derivative, polyethylene oxide, chitosans, and polycarbophil, or mixtures thereof.
7. A composition according to claim 1, wherein the acid insoluble polymer is selected from a group comprising methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, or mixtures thereof.
8. A composition according to claim 1, wherein the bioadhesive polymer is selected from a group comprising polycarbophil such as Noveon® AA1, and chitosans.

9. A composition according to claim 6, wherein the polymer system comprises methacrylic acid polymer and polycarbophil.
10. A composition according to claim 9, wherein the methacrylic acid polymer is selected from a group comprising Eudragit® L-100, Eudragit® RS, and Eudragit® LS.
- 5 11. A composition according to claims 1-10, which additionally comprises a cellulose derivative.
12. A composition according to claim 11, wherein the cellulose derivative is selected from a group comprising alkyl cellulose such as ethylcellulose and carboxyalkyl cellulose.
- 10 13. A composition according to claim 12, wherein the cellulose derivative is alkyl cellulose such as ethylcellulose.
14. A composition according to claims 9 to 13, wherein the ratio of methacrylic acid polymer and polycarbophil is 10:1 to 1:10 by weight of the composition.
15. A composition according to claim 1, wherein the pharmaceutically acceptable excipients are selected from the group comprising diluents disintegrants, binders, fillers, bulking agent, coating agents, plasticizers, organic solvents, colourants, stabilizers, preservatives, lubricants, glidants, chelating agents, and the like.
16. A composition according to claims 1-15, which is formulated as tablets or capsules.
17. A process for preparation of a composition according to claim 1 which comprises the following steps:
- 20 i) mixing of active ingredient(s) and polymer(s),  
ii) optionally adding one or more other pharmaceutically acceptable excipients, and  
iii) formulation of the mixture into a suitable dosage form.
18. A process according to claim 17, wherein said active ingredient is selected from a group comprising antibiotics, such as cephalosporins and penicillins, and their pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.
- 25 19. A process according to claim 17, wherein said active ingredient is amoxicillin trihydrate.
20. A process according to claim 17, wherein said active ingredient is cephalexin, or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.

21. A process according to claim 17, which comprises at least two active ingredients selected from the group comprising amoxicillin, ampicillin, cloxacillin, clavulonic acid, and cephalosporins, or pharmaceutically acceptable salts or derivatives thereof.
22. A process according to claim 17, wherein the polymer system comprises of polymers selected from a group comprising polyvinyl pyrrolidone, polyvinyl acetate, methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, cellulose derivative, polyethylene oxide, chitosans, and polycarbophil, or mixtures thereof.
- 10 23. A process according to claim 17, wherein the acid insoluble polymer is selected from a group comprising methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, or mixtures thereof.
- 15 24. A process according to claim 17, wherein bioadhesive polymer is selected from a group comprising polycarbophil such as Noveon® AA1, and chitosans.
25. A process according to claim 22, wherein the polymer system comprises methacrylic acid polymer and polycarbophil.
- 20 26. A process according to claim 25, wherein the methacrylic acid polymer is selected from a group comprising Eudragit® L-100, Eudragit® RS, and Eudragit® LS.
27. A process according to claims 17-26, wherein the composition additionally comprises a cellulose derivative.
28. A process according to claim 27, wherein the cellulose derivative is selected from a group comprising alkyl cellulose such as ethylcellulose and carboxyalkyl cellulose.
- 25 29. A process according to claim 28, wherein the cellulose derivative is alkyl cellulose such as ethylcellulose.
30. A process according to claims 25-29, wherein the ratio of methacrylic acid polymer and polycarbophil is 10:1 to 1:10 by weight of the composition.


31. The pharmaceutical composition substantially as herein described and illustrated by the examples.
32. The process for the preparation of a pharmaceutical composition substantially as herein described and illustrated by the examples.

5

Dated this 5<sup>th</sup> day of January, 2005

For Panacea Bioetc Ltd

10

  
Bhartee Gupta  
Authorized Signatory  
Manager (IP & Legal Affairs)

**Abstract**

05 JAN 2005

Rapidly disintegrating oral controlled release pharmaceutical compositions and process for preparation of such compositions are provided. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably amoxicillin either alone or in combination with other antibiotic(s). The controlled release compositions comprise at least one active ingredient, and a polymer system comprising of at least two polymers which retard the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in the alkaline contents of small intestine, optionally with other pharmaceutically acceptable excipients. The compositions provide therapeutically effective levels of the active ingredient for extended periods of time, and possess bioadhesive properties.

# **Document made available under the Patent Cooperation Treaty (PCT)**

International application number: PCT/IN05/000005

International filing date: 05 January 2005 (05.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: IN  
Number: 22/DEL/2004  
Filing date: 06 January 2004 (06.01.2004)

Date of receipt at the International Bureau: 25 May 2005 (25.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

This Page is inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLORED OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.  
As rescanning documents *will not* correct images  
problems checked, please do not report the  
problems to the IFW Image Problem Mailbox**